2495 related articles for article (PubMed ID: 26576089)
1. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
2. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.
Farra R; Grassi M; Grassi G; Dapas B
World J Gastroenterol; 2015 Aug; 21(30):8994-9001. PubMed ID: 26290628
[TBL] [Abstract][Full Text] [Related]
6. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Wang K; Kievit FM; Sham JG; Jeon M; Stephen ZR; Bakthavatsalam A; Park JO; Zhang M
Small; 2016 Jan; 12(4):477-87. PubMed ID: 26641029
[TBL] [Abstract][Full Text] [Related]
7. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
8. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.
Park J; Park J; Pei Y; Xu J; Yeo Y
Adv Drug Deliv Rev; 2016 Sep; 104():93-109. PubMed ID: 26686832
[TBL] [Abstract][Full Text] [Related]
10. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
11. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
12. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
13. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
[TBL] [Abstract][Full Text] [Related]
14. Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA.
Liang J; Zhang X; He S; Miao Y; Wu N; Li J; Gan Y
J Control Release; 2018 Sep; 286():348-357. PubMed ID: 30077738
[TBL] [Abstract][Full Text] [Related]
15. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
16. Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.
Zhang QY; Ho PY; Tu MJ; Jilek JL; Chen QX; Zeng S; Yu AM
Int J Pharm; 2018 Aug; 547(1-2):537-544. PubMed ID: 29894758
[TBL] [Abstract][Full Text] [Related]
17. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.
Yan JJ; Liao JZ; Lin JS; He XX
Tumour Biol; 2015 Jan; 36(1):55-67. PubMed ID: 25424700
[TBL] [Abstract][Full Text] [Related]
18. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
19. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review.
Varshosaz J; Taymouri S
Curr Pharm Des; 2015; 21(29):4310-28. PubMed ID: 26323421
[TBL] [Abstract][Full Text] [Related]
20. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
